Scientists test double and quadruple doses in bid for Longer-Lasting psoriasis relief

This small, completed study tested whether starting treatment for moderate-to-severe plaque psoriasis with double or quadruple the standard dose of the drug risankizumab could lead to better and longer-lasting skin clearance. Researchers wanted to see if these higher doses more effectively reduced certain immune cells in the skin thought to cause psoriasis to return. The study involved 20 adults and measured skin clearance and safety over one year.